profit from every $100 of sales.
$0$100
Kazia Therapeutics
$6.62-4.75% today
-9.2% in 1 year
1-year low $5.001-year high $16.90
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2024 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Kazia Therapeutics sold, what it kept, and what it did with the cash.
Sales went from A$0 in 2022 to A$42,000 in 2025, with -A$20.7 million of profit last year.
SalesProfit
Kazia Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Kazia Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Kazia Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 2 | 0 | |
| – | – | – | – | |
| -25 | -24 | -28 | -14 | |
| -24 | -22 | -27 | -13 | |
| -25 | -20 | -27 | -21 | |
| -93.05 | -56.15 | – | -18.90 | |
| – | – | – | – | |
| – | – | -1,233.2% | -33,850.0% | |
| – | – | -1,160.2% | -49,290.5% |
Balance sheet
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 36 | 28 | 22 | 6 |
| Cash | 7 | 5 | 2 | 4 |
| Total debt | 2 | 2 | 1 | 0 |
| Total liabilities | 18 | 16 | 32 | 14 |
| 18 | 12 | -10 | -8 | |
| 1 | 2 | – | 1 | |
| -99.7% | -137.8% | – | – | |
| -136.9% | -169.8% | 267.3% | 249.4% |
Cash flow
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -23 | -15 | -10 | -13 | |
| – | – | – | – | |
| -23 | -15 | -10 | -13 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 1 | 1 | 1 |
Valuation
- –
- –
- –
- 1.2×
- 3,617.9×
- –
- –
- -8.7%
- -13.6%
- 0.0%
Profitability
- 100.0%
- -33,850.0%
- -49,290.5%
- -92,090.1%
- -36.2%
- 50.6%
- -116.9%
- -31.4%
- -38.9%
- 39,859.3%
Growth
- −98.2%
- –
- −38.6%
- –
- +46.9%
Financial health
- -0.3×
- 0.00
- 0.1%
- –
- 2.87
- 2.87
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 12%of 952
Bottom 1%of 887
Bottom 11%of 987
What analysts expect
- Average price target
- $21.50
- Range
- $18.00 – $25.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 16, 2026 | -0.81 | -0.01 | −11,521.2% |
| Jun 30, 2025 | -4.18 | -0.01 | −63,968.6% |
| May 28, 2025 | -7.61 | -10.76 | +29.3% |
| Nov 19, 2024 | -20.81 | -15.00 | −38.7% |
| Mar 27, 2024 | -12.53 | – | – |
| Nov 27, 2023 | -10.02 | -1.66 | −504.8% |
| Mar 9, 2023 | -31.86 | -24.65 | −29.3% |
| Oct 6, 2022 | -30.53 | – | – |
News
Kazia gains as Guggenheim is latest to initiate at Buy on lead assetSeeking Alpha · Oct 21, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
4/6Passes 4 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
51No pass
Benjamin Graham
66Pass
Philip Fisher
70Pass
Peter Lynch
–Not enough data
Joel Greenblatt
4No pass
Charlie Munger
72Pass
Terry Smith
64Pass
Questions about Kazia Therapeutics
Is Kazia Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 4 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Kazia Therapeutics AI analysis
What does Kazia Therapeutics do?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is in Biotechnology.
Does Kazia Therapeutics pay a dividend?
No. Kazia Therapeutics does not pay a dividend at the moment.
Is Kazia Therapeutics stock halal?
Yes. Kazia Therapeutics passes our halal screen: its business is permitted and its debt is 0.3% of its market value, under the 30% limit. How we check
How has Kazia Therapeutics stock done over the past year?
Down 9.2% over the past twelve months, to $6.62. It traded between $5.00 and $16.90 and is 60.8% below its high.
Who are Kazia Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Kazia Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.